Search results for " administration"

showing 10 items of 4299 documents

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

2012

BACKGROUND: Some patients with severe asthma have recurrent asthma exacerbations associated with eosinophilic airway inflammation. Early studies suggest that inhibition of eosinophilic airway inflammation with mepolizumab-a monoclonal antibody against interleukin 5-is associated with a reduced risk of exacerbations. We aimed to establish efficacy, safety, and patient characteristics associated with the response to mepolizumab. METHODS: We undertook a multicentre, double-blind, placebo-controlled trial at 81 centres in 13 countries between Nov 9, 2009, and Dec 5, 2011. Eligible patients were aged 12-74 years, had a history of recurrent severe asthma exacerbations, and had signs of eosinophil…

AdultMalemedicine.medical_specialtyAdolescentPlacebo-controlled studyFevipiprantAntibodies Monoclonal HumanizedPlaceboLebrikizumabDrug Administration ScheduleLeukocyte CountYoung Adultchemistry.chemical_compoundDouble-Blind MethodReslizumabInternal medicineSecondary PreventionmedicineHumansAnti-Asthmatic AgentsPulmonary EosinophiliaChildGlucocorticoidsAgedAsthmaDose-Response Relationship Drugbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseBenralizumabAsthmaEosinophilsTreatment OutcomechemistryPhysical therapyDrug Therapy CombinationFemaleInterleukin-5businessMepolizumabmedicine.drugThe Lancet
researchProduct

Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large mu…

2011

In β-thalassemia major (β-TM) patients, iron chelation therapy is mandatory to reduce iron overload secondary to transfusions. Recommended first line treatment is deferoxamine (DFO) from the age of 2 and second line treatment after the age of 6 is deferiprone (L1). A multicenter randomized open-label trial was designed to assess the effectiveness of long-term alternating sequential L1-DFO versus L1 alone iron chelation therapy in β-TM patients. Deferiprone 75 mg/kg 4 days/week and DFO 50 mg/kg/day for 3 days/week was compared with L1 alone 75 mg/kg 7 days/week during 5-year follow-up. A total of 213 thalassemia patients were randomized and underwent intention-to-treat analysis. Statisticall…

AdultMalemedicine.medical_specialtyAdolescentPyridonesThalassemiaClinical BiochemistryDeferoxamineIron Chelating AgentsGastroenterologyDrug Administration Schedulelaw.inventionchemistry.chemical_compoundYoung AdultRandomized controlled triallawInternal medicineMedicineHumansDeferiproneAdverse effectGenetics (clinical)Survival analysisbusiness.industryBiochemistry (medical)Serum ferritin levelbeta-ThalassemiaHematologyIron chelation therapymedicine.diseaseChelation TherapyDeferoxamineTreatment OutcomechemistryDrug Therapy CombinationFemalebusinessDeferiproneThalassemia Iron overload Iron chelation therapy Deferiprone (L1) Deferroxamine (DFO)medicine.drugFollow-Up StudiesHemoglobin
researchProduct

Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy

2014

Abstract Background Infliximab is effective as rescue therapy in severe corticosteroid-refractory ulcerative colitis. The optimal dose regimen and the long term benefits are not well defined. The aim of the present study was to evaluate short- and long-term colectomy rate in a cohort of patients with severe corticosteroid-refractory ulcerative colitis who received a three-dose infliximab induction regimen. Methods One hundred and thirteen patients admitted to 11 Italian IBD referral centres and treated with infliximab according to an intention to treat three-dose regimen were included. The co-primary endpoints were 3- and 12-month colectomy rate. The secondary end-points were the overall co…

AdultMalemedicine.medical_specialtyAdolescentSettore MED/12 - GASTROENTEROLOGIAmedicine.medical_treatmentUlcerative colitis;GastroenterologyDrug Administration ScheduleYoung AdultAdrenal Cortex HormonesInternal medicineHumansMedicineTreatment FailureAdverse effectColectomyInfliximab;AgedColectomyIntention-to-treat analysisbusiness.industryAnti-Inflammatory Agents Non-SteroidalGastroenterologyAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseUlcerative colitisInfliximabInfliximabRegimenTreatment OutcomeUlcerative colitisRelative riskCohortColitis UlcerativeFemalebusinessmedicine.drugJournal of Crohn's and Colitis
researchProduct

Refinements in buccal mucosal graft urethroplasty for hypospadias repair

1998

We evaluated our experience with buccal mucosa in urethral reconstruction for complex hypospadias repair in a total of 62 children operated on at our institution since 1990 at a mean follow-up of 23 months. After the graft had been taken from the lower lip, with possible extension to the inner cheek, complete thinning of the graft was performed. The graft was then sutured in an onlay fashion to the urethral plate, and suprapubic urinary diversion was carried out for 3 weeks. The overall complication rate in this rather complex series of patients, including 26 "hypospadias cripples," was 13%; the complications involved 4 fistulas, 3 cases of graft necrosis, and only 1 meatal stenosis during …

AdultMalemedicine.medical_specialtyAdolescentUrologyUrethroplastymedicine.medical_treatmentUrethramedicineHypospadias repairHumansChildHypospadiasbusiness.industryGraft SurvivalUrinary diversionMouth MucosaSkin TransplantationBuccal administrationCheekmedicine.diseaseMeatal stenosisSurgeryPlastic surgeryTreatment Outcomemedicine.anatomical_structureEvaluation Studies as TopicHypospadiasChild PreschoolbusinessFollow-Up StudiesWorld Journal of Urology
researchProduct

Treatment of human brucellosis with rifampin plus minocycline

2003

In order to evaluate the efficacy and tolerability of a high intravenous dose of rifampin plus oral minocycline (administered daily for 3 weeks) for the treatment of acute brucellosis, we retrospectively reviewed the outcome of 239 consecutive patients (135 adults and 104 children) diagnosed and treated over a 17-year period in Italy. The combination used resulted in 100% response and a relapse rate lower than 2%. Fifty-two (30 adults and 22 children) (29.8%) complained of mild adverse effects including an increase in aspartate aminotransferase (>250 IU) observed in 12 cases and considered related to rifampin and in 11 cases a reversible hyperpigmentation of the tongue attributed to minocyc…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentMinocyclineRisk AssessmentDrug Administration SchedulePharmacotherapyRecurrenceInternal medicinemedicineHumansPharmacology (medical)ChildInfusions IntravenousAdverse effectAgedRetrospective StudiesAntibacterial agentAged 80 and overPharmacologyChemotherapyDose-Response Relationship Drugbusiness.industryRetrospective cohort studyMinocyclineMiddle AgedBrucellaSurgeryTreatment OutcomeInfectious DiseasesItalyOncologyTolerabilityChild PreschoolbrucellosisDrug Therapy CombinationFemaleRifampinbusinessRifampicinFollow-Up Studiesmedicine.drug
researchProduct

Apomorphine-Induced Growth Hormone Response Is Attenuated by Ethanol but Not Dextromethorphan

2007

Background: Misuse of alcohol drinking is a major health problem. Alcohol decreases spontaneous growth hormone (GH) secretion, but the mechanism is unclear. The aim of this study was to test whether administration of alcohol (study 1) or a N-methyl d-aspartate (NMDA) receptor antagonist (study 2) attenuates the GH response to pharmacological dopaminergic stimulation. Methods: The 2-session repeated measures design was conducted at the endocrine laboratory at the Department of Psychiatry at the Free University Berlin. Twenty healthy Caucasian males aged 35±10 years without a history of alcohol use disorders were tested using the Apomorphine (APO) challenge test. In study 1, we injected APO (…

AdultMalemedicine.medical_specialtyApomorphineMedicine (miscellaneous)PharmacologyToxicologyPlaceboDextromethorphanReceptors N-Methyl-D-Aspartatechemistry.chemical_compoundOral administrationInternal medicinemedicineHumansEthanolEthanolHuman Growth Hormonebusiness.industryDopaminergicCentral Nervous System DepressantsDextromethorphanGrowth hormone secretionApomorphinePsychiatry and Mental healthEndocrinologychemistryArea Under CurveDopamine AgonistsNMDA receptorbusinessmedicine.drugAlcoholism: Clinical and Experimental Research
researchProduct

Critical issues for employees in inter-municipal health care services: a multiple case study

2018

Abstract Background Traditional, hierarchical government structures have recently been challenged by increased complexity, fragmented services and heavy public demand. When healthcare services become fragmented and decentralised, they require redesign. Inter-municipal cooperation is a strategy to deal with current challenges and future demographic changes. Few studies exist that can help us conceptualize challenges regarding employment in this context and inform managers in the involved municipalities. This study aims to identify critical issues for employees in inter-municipal health care services and to elaborate on how and why these issues are experienced. Methods A multiple qualitative …

AdultMalemedicine.medical_specialtyAttitude of Health PersonnelInterprofessional RelationsContext (language use)Health informaticsHealth administrationYoung Adult0502 economics and businessHealth care050602 political science & public administrationHumansMedicineCooperative BehaviorQualitative ResearchGovernmentNorwayInter-municipal cooperation (IMC)Reformbusiness.industrylcsh:Public aspects of medicineHealth PolicyNursing researchPublic health05 social sciencesSocial SupportCaselcsh:RA1-1270Health ServicesMiddle AgedPublic relations0506 political scienceCooperationInterinstitutional RelationsHealthHealth Care ReformMunicipalityMultiple caseEmployeeFemalebusiness050203 business & managementResearch ArticleBMC Health Services Research
researchProduct

Use of topical tranexamic acid in primary total hip arthroplasty. Efficiency and safety. Our experience.

2019

Abstract Background and aim Intravenous tranexamic acid has been shown to reduce bleeding and the need for transfusions in total hip arthroplasty, although it has a theoretical risk of producing thromboembolic phenomena. Recently some papers have been published using the topical application of tranexamic acid, but the ideal administration protocol has not yet been clearly defined. The aim of this paper was to demonstrate that our protocol of topical tranexamic acid is effective and safe. Methods Prospective data collection from a case series of 80 primary hip arthroplasties, in which the following topical tranexamic acid protocol is used: 1.5 g diluted to a total volume of 60 ml were admini…

AdultMalemedicine.medical_specialtyBlood transfusionAdministration TopicalArthroplasty Replacement Hipmedicine.medical_treatmentBlood Loss SurgicalProspective data030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineClinical ProtocolsmedicineHumansBlood TransfusionOrthopedics and Sports MedicineProspective StudiesAged030222 orthopedicsAdministración tópica Artroplastia total cadera Topical administration Total hip arthroplasty Tranexamic acid Ácido tranexámicobusiness.industryFemoral canalMiddle AgedAntifibrinolytic AgentsSurgeryTreatment Outcomemedicine.anatomical_structureTranexamic AcidAcido tranexamicoFemaleSurgerybusinessTranexamic acidmedicine.drugTotal hip arthroplasty
researchProduct

Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular weight heparin.

2009

Introduction: We tested the efficacy and safety of fixed doses of Low-Molecular Weight Heparin (LMWH) in patients requiring interruption of Vitamin-k Antagonist (VKA) because of invasive procedures Methodology: Pre-operatively, patients discontinued VKA 5 +/- 1days; in those at low-risk for thrombosis, LMWH was given at a prophylactic dosage of 3.800 U.I. (nadroparin) or 4.000 U.I. (enoxaparin) anti-FXa once daily the night before the procedure. In patients at high-risk for thrombosis, LMWH was started early after VKA cessation and given at fixed sub-therapeutic doses (3.800 or 4.000 UI anti-FXa twice daily) until surgery. Post-operatively, LMWH was reinitiated 12 hours after procedure whil…

AdultMalemedicine.medical_specialtyBridging low molecular weight heparinTime FactorsVitamin Kmedicine.drug_classLow molecular weight heparinAdministration OralPostoperative HemorrhageRisk AssessmentDrug Administration ScheduleSettore MED/15 - Malattie Del SangueRisk FactorsThromboembolismmedicineHumansProspective StudiesEnoxaparinProspective cohort studyAgedAged 80 and overbusiness.industryIncidence (epidemiology)WarfarinAnticoagulantsNadroparinHematologyHeparinHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombosisConfidence intervalSurgeryLow Molecular Weight Heparin Fixed doses Chronic oral anticoagulation perioperative bridgingAnesthesiaSurgical Procedures OperativeNadroparinFeasibility StudiesFemaleWarfarinbusinessmedicine.drugFactor Xa Inhibitors
researchProduct

Transfusion-associated chronic hepatitis C: alpha-n1 interferon for 6 vs. 12 months.

1996

Abstract Aims: To compare the long-term effects of brief and prolonged therapy with alpha-n 1 interferon for transfusion-associated chronic hepatitis C. Methods: One hundred and sixteen subjects (male/female 4868, mean age 46.9 years) were studied. Sixty patients were randomised to brief treatment (group 1: interferon 5 Mu/msq. t.i.w. for 2 months, then 3 Mu/msq. t.i.w. for 4 months), and 56 to prolonged treatment (group 2: interferon 5 Mu/msq. t.i.w. for 2 months, then 3 Mu/msq. t.i.w. for 10 months). All were followed for 12 months after stopping interferon. Results: The early response rate was 47.4% (Group 1 [45%], Group 2 [50%]). No "breakthrough" reactivations were observed. The early …

AdultMalemedicine.medical_specialtyCirrhosisAdolescentmedicine.medical_treatmentHepatitis C virusPopulationAlpha interferonmedicine.disease_causeGastroenterologyAntibodiesDrug Administration ScheduleInterferonInternal medicinemedicineHumanseducationInterferon alfaAgededucation.field_of_studyHepatologybusiness.industryInterferon-alphaTransfusion ReactionImmunotherapyMiddle Agedmedicine.diseaseHepatitis CSurgeryChronic DiseaseFemalebusinessComplicationmedicine.drugJournal of hepatology
researchProduct